Trevi Therapeutics Inc (TRVI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $14.95 (-1.71%), Market cap $2.06B, 52-week low–high $5.47 ~ $15.40.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbup
Financial statements, price targets, institutional (13F) holdings and related news for Trevi Therapeutics Inc are updated in real time on BlackAll Trade.
Trevi Therapeutics Inc trades at $14.95 (-1.71%). Real-time quotes and charts are available on BlackAll Trade.
Trevi Therapeutics Inc has a market cap of about $2.06B.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibro